CHIR Chiron (MM)

Chiron Corporation (NASDAQ:CHIR) today issued the following statement in response to a letter received today from ValueAct Capital: We continue to believe that ValueAct should want to meet with Chiron's independent directors and management team to fully understand the serious challenges facing the Company and to gain a realistic perspective on our future prospects. Our independent directors and management team continue to strongly recommend the Novartis transaction and believe that it represents a full and fair price and is a superior alternative for Chiron's public stockholders to Chiron remaining a standalone company. About Chiron Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information about Chiron, please visit www.chiron.com.